It was reported on Tuesday that US-based Nephron Pharmaceuticals Corporation has received approval from US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application of Ketorolac Tromethamine Injection USP, 60mg/2mL (30mg/mL) in single-dose vials.
The vials are prepared from polypropylene plastic with a 'luer lock' interface for needle-free dosing and made using Blow-Fill-Seal technology.
The product has become one of the first Abbreviated New Drug Application-approved non-respiratory generic medications developed by the company as it aims to grow, with it also receiving USFDA approval for Sodium Chloride IV Bags earlier this year.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream